BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Springett GM, Hoffe SE. Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control. 2008;15:295-307. [PMID: 18813197 DOI: 10.1177/107327480801500404] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Bellomi M, Viotti S, Preda L, D’andrea G, Bonello L, Petralia G. Perfusion CT in solid body-tumours part II. Clinical applications and future development. Radiol med 2010;115:858-74. [DOI: 10.1007/s11547-010-0545-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
2 Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54:979-985. [PMID: 25734581 DOI: 10.3109/0284186x.2015.1004367] [Cited by in Crossref: 112] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis]
3 Barugola G, Partelli S, Crippa S, Capelli P, D’Onofrio M, Pederzoli P, Falconi M. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203:132-139. [PMID: 21824596 DOI: 10.1016/j.amjsurg.2011.03.008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
4 Zaky AM, Wolfgang CL, Weiss MJ, Javed AA, Fishman EK, Zaheer A. Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning. RadioGraphics 2017;37:93-112. [DOI: 10.1148/rg.2017160054] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
5 Shukla PJ. The challenges of improving survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 2011;254:385-6; author reply 386. [PMID: 21677560 DOI: 10.1097/SLA.0b013e31822682b7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Mullapudi B, Hawkes PJ, Patel A, Are C, Misra S. Borderline resectable pancreatic cancer. Indian J Surg Oncol 2015;6:63-8. [PMID: 25937766 DOI: 10.1007/s13193-014-0374-8] [Reference Citation Analysis]
7 Lee KJ, Yoon HI, Chung MJ, Park JY, Bang S, Park SW, Seong JS, Song SY. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. Gut Liver 2016;10:303-9. [PMID: 26470767 DOI: 10.5009/gnl15186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
8 Mellon EA, Strom TJ, Hoffe SE, Frakes JM, Springett GM, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. J Gastrointest Oncol. 2016;7:547-555. [PMID: 27563444 DOI: 10.21037/jgo.2016.03.15] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
9 Kang CM, Chung YE, Park JY, Sung JS, Hwang HK, Choi HJ, Kim H, Song SY, Lee WJ. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg. 2012;16:509-517. [PMID: 22183861 DOI: 10.1007/s11605-011-1784-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
10 Zakharova OP, Karmazanovsky GG, Egorov VI. Pancreatic adenocarcinoma: Outstanding problems. World J Gastrointest Surg 2012; 4(5): 104-113 [PMID: 22655124 DOI: 10.4240/wjgs.v4.i5.104] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
11 Partelli S, Crippa S, Barugola G, Tamburrino D, Capelli P, D’Onofrio M, Pederzoli P, Falconi M. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection. Ann Surg Oncol. 2011;18:3608-3614. [PMID: 21584836 DOI: 10.1245/s10434-011-1769-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sun K, Li W, Han J, Wu H. Comparative effectiveness of primary tumor resection in patients with stage III pancreatic adenocarcinoma. BMC Cancer 2019;19:761. [PMID: 31370893 DOI: 10.1186/s12885-019-5966-9] [Reference Citation Analysis]
13 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
14 Yang W, Fan Z, Deng Z, Pang J, Bi X, Fraass BA, Sandler H, Li D, Tuli R. Novel 4D-MRI of tumor infiltrating vasculature: characterizing tumor and vessel volume motion for selective boost volume definition in pancreatic radiotherapy. Radiat Oncol 2018;13:191. [PMID: 30285889 DOI: 10.1186/s13014-018-1139-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Stevens L, Pathak S, Nunes QM, Pandanaboyana S, Macutkiewicz C, Smart N, Smith AM. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB (Oxford) 2015;17:285-91. [PMID: 25431369 DOI: 10.1111/hpb.12355] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
16 Dai MH, Zamarin D, Gao SP, Chou TC, Gonzalez L, Lin SF, Fong Y. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br J Surg. 2010;97:1385-1394. [PMID: 20629009 DOI: 10.1002/bjs.7124] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
17 Auriemma WS, Berger AC, Bar-ad V, Boland PM, Cohen SJ, Roche-lima CMS, Morris GJ. Locally Advanced Pancreatic Cancer. Seminars in Oncology 2012;39:e9-e22. [DOI: 10.1053/j.seminoncol.2012.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
18 Shrikhande SV, Arya S, Barreto SG, Ingle S, D'souza MA, Hawaldar R, Shukla PJ. Borderline resectable pancreatic tumors: Is there a need for further refinement of this stage? Hepatobiliary & Pancreatic Diseases International 2011;10:319-24. [DOI: 10.1016/s1499-3872(11)60053-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Castellanos E, Berlin J, Cardin DB. Current treatment options for pancreatic carcinoma. Curr Oncol Rep 2011;13:195-205. [PMID: 21491194 DOI: 10.1007/s11912-011-0164-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
20 Egorov VI, Petrov RV, Lozhkin MV, Maynovskaya OA, Starostina NS, Chernaya NR, Filippova EM. Liver blood supply after a modified Appleby procedure in classical and aberrant arterial anatomy. World J Gastrointest Surg 2013; 5(3): 51-61 [PMID: 23556062 DOI: 10.4240/wjgs.v5.i3.51] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
21 Morelli L, Berchiolli R, Guadagni S, Palmeri M, Furbetta N, Gianardi D, Bianchini M, Funel N, Caprili G, Pollina LE, Di Candio G, Mosca F, Di Franco G, Cuschieri A. Pancreatoduodenectomy without Vascular Resection in Patients with Primary Resectable Adenocarcinoma and Unilateral Venous Contact: A Matched Case Study. Gastroenterol Res Pract 2018;2018:1081494. [PMID: 30595690 DOI: 10.1155/2018/1081494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Jeffrey RB. Pancreatic cancer: radiologic imaging. Gastroenterol Clin North Am 2012;41:159-77. [PMID: 22341256 DOI: 10.1016/j.gtc.2011.12.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
23 Rezai P, Yaghmai V, Tochetto SM, Galizia MS, Miller FH, Mulcahy MF, Small W. Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT. International Journal of Radiation Oncology*Biology*Physics 2011;81:452-9. [DOI: 10.1016/j.ijrobp.2010.05.060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
24 Roy R, Maraveyas A. Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist. 2010;15:259-269. [PMID: 20203172 DOI: 10.1634/theoncologist.2009-0272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
25 Oh TG, Chung MJ, Bang S, Park SW, Chung JB, Song SY, Seong J, Kang CM, Lee WJ, Park JY. Validation of group B borderline resectable pancreatic cancer: retrospective analysis. Gut Liver 2014;8:557-62. [PMID: 25228978 DOI: 10.5009/gnl13264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C, Pederzoli P, Falconi M. Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol. 2009;16:3316-3322. [PMID: 19707831 DOI: 10.1245/s10434-009-0670-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 8.2] [Reference Citation Analysis]
27 Padbury RTA. Survival from pancreatic cancer: it's not just about the surgical mortality. Medical Journal of Australia 2012;196:491-2. [DOI: 10.5694/mja12.10545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
28 Shrikhande SV, Barreto SG. Surgery for pancreatic carcinoma: state of the art. Indian J Surg. 2012;74:79-86. [PMID: 23372311 DOI: 10.1007/s12262-011-0373-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
29 Syed AR, Carleton NM, Horne Z, Dhawan A, Bedi G, Kochhar G, Morrissey S, Williams H, Atkinson D, Schiffman S, Monga D, Lupetin A, Kirichenko A, Mitre M, Dhawan M, Kulkarni A, Thakkar S. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy. J Gastrointest Cancer 2020;51:836-43. [PMID: 31605289 DOI: 10.1007/s12029-019-00303-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]